## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dharmaraj Ramachandra Rao, et al. § Group Art Unit: 1614 Serial No.: 10/577,714 80000000 Examiner: Not assigned Filed: May 2, 2006 Confirmation No.: 5756

For: PROCESS FOR THE PREPARATION OF POLYMORPHS OF SELECTIVE SEROTONIN

REUPTAKE INHIBITOR

## CERTIFICATE OF FILING

Office

Pursuant to 37 C.F.R. §1.8, I hereby certify that this Commissioner for Patents correspondence is being electronically submitted to the PO Box 1450 and Trademark Patent Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

## Commissioner:

This Information Disclosure Statement, including completed Forms PTO/SB/08A&B, comprises a list of pertinent art of which Applicants are aware. In accordance with 37 C.F.R. 1.98, no paper copies of the U.S. Patents and patent applications are enclosed. Copies of the foreign documents listed on Forms PTO/SB/08A&B are enclosed herewith.

Atty Docket: PAC/eehc/23398US (4137-00900)

Patent

The submission of this Information Disclosure Statement and Forms PTO/SB/08A&B is not an admission that the art cited is "prior" with respect to the present invention, nor is it a representation that a search has been conducted or that no better art exists. Applicants reserve the right to swear behind or otherwise disprove any alleged "prior" nature of any art cited should the facts support and that situation warrant such an action. It is submitted that the art cited does not constitute a bar to the patentability of Applicants' invention under 35 U.S.C. §§ 102 or 103.

Applicants believe that no fee is due for the filing of this Information Disclosure Statement.

Nonetheless, in the event that a fee is due, please charge it to Deposit Account No. 50-1515 of Conley Rose, P.C.

Respectfully submitted,

CONLEY ROSE, P.C.

Rodney B. Carroll Reg. No. 39,624

ATTORNEY FOR APPLICANTS

Date: 12-18-06

5700 Granite Parkway, Suite 330 Plano, Texas 75024 (972) 731-2288 (972) 731-2289 Facsimile

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/577,714 Filing Date May 2, 2006 INFORMATION DISCLOSURE First Named Inventor Dharmaraj Ramachandra Rao STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) Examiner Name N/A Attorney Docket Number PAC/eehc/23398US (4137-00900)

Sheet

Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	<sup>US-</sup> 4,536,518	08/20/1985	Welch, Jr. et al.		
	AB	US- 5,248,699	09/28/1993	Sysko, et al.		
	AC	US- 5,734,083	03/31/1998	Wilson, et al.		
	AD	<sup>US-</sup> 6,452,054 B2	09/17/2002	Aronhime, et al.		
	AE	<sup>US-</sup> 6,495,721 B1	12/17/2002	Schwartz, et al.		
	AF	<sup>US-</sup> 6,500,987 B1	12/31/2002	Schwartz, et al.		
	AG	<sup>US-</sup> 6,517,866 B1	02/11/2003	Am Ende, et al.		
	AH	US- 6,600,073 B1	07/29/2003	Schwartz, et al.		
	AI .	US- 6,858,652 B2	02/22/2005	Aronhime, et al.		
	AJ	US- 2002/0183555 A1	12/05/2002	Schwartz, et al.		
	AK	US- 2003/0055112 A1	03/20/2003	Schwartz, et al.		
		US-	•			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Dete	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whare Relevant Passages	T
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	BA	WO 01/32601 A1	05/10/2001	CIBA Specialty Chemicals Holding		
	ВВ	WO 01/45692 A1	06/28/2001	TEVA Pharmaceutical Industries Ltd		
	вс	WO 03/093217 A1	11/13/2003	TEVA Pharmaceutical Industries Ltd		
						L
						L

Examiner	 Date	
Signature	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformence with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Petent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MIPEP 901-04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese petent documents, the inclusion of the year of the reign of the Emperor must precede the serial number of the patent document, but of document with the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is ettached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an epplication. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, Including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent end Trademark Office, P.O. Box 1450, Alexendrie, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
Guosata	te 10 10mm (443)	.0		Application Number	10/577,714	
INFORMATION DISCLOSURE				Filing Date	May 2, 2006	
STA	STATEMENT BY APPLICANT			First Named Inventor	Dharmaraj Ramachandra Rao	
(Use as many sheets as necessery)			anners!	Art Unit	1614	
			ecessery)	Examiner Name	N/A	
Sheet	2	of	2	Attorney Docket Number	PAC/eehc/23398US (4137-00900)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	International Search Report and Written Opinion, PCT/GB2004/004672, May 17, 2005, 14 pgs.	
	СВ	International Preliminary Report on Patentability, PCT/GB2004/004672, May 17, 2005, 11 pgs.	
	СС	HALEBLIAN, JOHN K., et al., "Characterizetion of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications," Journal of Pharmaceutical Sciences, Vol. 64. No. 8, August 1975, pgs. 1269-1288.	
	CD	ALMARSSON, ÖRN, et al., "High-Throughput Surveys of Crystal Form Diversity of Highly Polymorphic Pharmaceutical Compounds," XP-002295000, American Chemical Society, Crystal Growth & Design, Vol. 3, No. 6, 2003, pgs. 927-933.	
	CE	REMENAR, JULIUS F., et al., "Salt Selection and Simultaneous Polymorphism Assessment via High- Throughput Crystallizetion: The Case of Sertreline," American Chemical Society, Organic Process Research & Development, Vol. 7, No. 6, 2003, pgs. 990-996.	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optionel). 2 Applicant is to piece a check merk here if English language Trensletion is atteched.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, prepering, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandrie, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: